This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Merit Medical Systems Launches...
Business product launch

Merit Medical Systems Launches Resilience Esophageal Stent

Analysis based on 7 articles · First reported Mar 16, 2026 · Last updated Mar 16, 2026

Sentiment
30
Attention
2
Articles
7
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The US commercial release of the Resilience Through-the-Scope (TTS) Esophageal Stent by Merit Medical Systems is expected to positively impact the medical devices market, particularly in the endoscopy segment. This innovation could lead to increased revenue and market share for Merit Medical Systems, as it addresses unmet clinical needs and offers improved patient care.

Medical Devices Healthcare
Event Summary

Merit Medical Systems, Inc. announced the US commercial release of its new Resilience Through-the-Scope (TTS) Esophageal Stent on March 16, 2026. This new product, part of Merit Medical Systems' Endoscopy portfolio, is designed for the treatment of esophageal fistulas and strictures caused by malignant tumors. The Resilience stent features proprietary anti-migration flanges, a single-handed deployment system, and unique size offerings, aiming to provide greater migration resistance and ease of placement compared to currently available TTS stents. Martha G. Aronson, President and CEO of Merit Medical Systems, highlighted the stent's role in advancing care, while Stuart K. Amateau from the M Health Fairview University of Minnesota Medical Center praised its ability to fulfill an unmet clinical need.

Key Actions
100 Merit Medical Systems commercially released new medical device
Entities Involved
stock
Merit Medical Systems
Merit Medical Systems announced the US commercial release of its new Resilience Through-the-Scope (TTS) Esophageal Stent, expanding its Endoscopy portfolio and potentially increasing its market share in the rapidly growing TTS stent-technology market.
Importance 100 Sentiment 40
per
Martha G. Aronson
Martha G. Aronson, President and CEO of Merit Medical Systems, emphasized that the Resilience stent addresses clinical disadvantages of existing TTS esophageal stents and signifies a step forward in the TTS stent-technology market.
Importance 40 Sentiment 30
per
Stuart K. Amateau
Stuart K. Amateau, a Professor and Chief Division of Gastroenterology, Hepatology, and Nutrition at the M Health Fairview University of Minnesota Medical Center, provided a positive endorsement of the Resilience TTS Esophageal Stent, highlighting its unique features and ability to fulfill an unmet need.
Importance 30 Sentiment 20
priv
M Health Fairview University of Minnesota Medical Center
The M Health Fairview University of Minnesota Medical Center is mentioned as the affiliation for Stuart K. Amateau, who provided an expert opinion on the Resilience stent.
Importance 10 Sentiment 0
Relationships
Martha G. Aronson related ↔ Merit Medical Systems
Stuart K. Amateau related ↔ M Health Fairview University of Minnesota Medical Center
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.